FMR LLC lowered its stake in Repligen Corporation (NASDAQ:RGEN) by 3.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,256,030 shares of the biotechnology company’s stock after selling 41,930 shares during the period. FMR LLC owned approximately 3.71% of Repligen Corporation worth $44,212,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the company. Norges Bank acquired a new position in Repligen Corporation during the fourth quarter worth $8,527,000. Macquarie Group Ltd. increased its position in Repligen Corporation by 481.1% in the fourth quarter. Macquarie Group Ltd. now owns 319,668 shares of the biotechnology company’s stock worth $9,852,000 after buying an additional 264,659 shares during the period. Cortina Asset Management LLC acquired a new position in Repligen Corporation during the first quarter worth $6,515,000. State Street Corp increased its position in Repligen Corporation by 12.3% in the fourth quarter. State Street Corp now owns 1,059,196 shares of the biotechnology company’s stock worth $32,643,000 after buying an additional 116,068 shares during the period. Finally, Conestoga Capital Advisors LLC increased its position in Repligen Corporation by 8.6% in the first quarter. Conestoga Capital Advisors LLC now owns 1,215,810 shares of the biotechnology company’s stock worth $42,797,000 after buying an additional 95,942 shares during the period. 98.57% of the stock is owned by institutional investors.

Shares of Repligen Corporation (RGEN) traded up 1.10% on Thursday, hitting $41.44. 555,527 shares of the stock were exchanged. The stock has a market cap of $1.53 billion, a price-to-earnings ratio of 106.26 and a beta of 1.31. Repligen Corporation has a 1-year low of $26.16 and a 1-year high of $46.81. The stock’s 50-day moving average is $41.28 and its 200-day moving average is $36.10.

Repligen Corporation (NASDAQ:RGEN) last announced its earnings results on Thursday, August 3rd. The biotechnology company reported $0.20 EPS for the quarter, beating analysts’ consensus estimates of $0.15 by $0.05. The firm had revenue of $32.40 million for the quarter, compared to analysts’ expectations of $31.72 million. Repligen Corporation had a return on equity of 9.57% and a net margin of 11.93%. Repligen Corporation’s quarterly revenue was up 11.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.16 EPS. Analysts forecast that Repligen Corporation will post $0.56 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Fmr LLC Has $44.21 Million Position in Repligen Corporation (RGEN)” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another website, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/08/03/repligen-corporation-rgen-shares-sold-by-fmr-llc-updated-updated-updated.html.

A number of research firms recently weighed in on RGEN. BidaskClub downgraded shares of Repligen Corporation from a “strong-buy” rating to a “buy” rating in a research report on Monday. Zacks Investment Research downgraded shares of Repligen Corporation from a “buy” rating to a “hold” rating in a research report on Tuesday, June 6th. First Analysis reaffirmed an “equal weight” rating and issued a $40.00 target price on shares of Repligen Corporation in a research report on Friday, April 21st. William Blair started coverage on shares of Repligen Corporation in a research report on Friday, July 21st. They issued an “outperform” rating for the company. Finally, Jefferies Group LLC reissued a “hold” rating and issued a $40.00 price objective (up previously from $33.00) on shares of Repligen Corporation in a research report on Wednesday, June 28th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $41.20.

About Repligen Corporation

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.

Institutional Ownership by Quarter for Repligen Corporation (NASDAQ:RGEN)

Receive News & Stock Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related stocks with our FREE daily email newsletter.